dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Abrisqueta, Pau |
dc.contributor.author | Medina Gil, Daniel |
dc.contributor.author | Lu, Junyan |
dc.contributor.author | Alcoceba, Miguel |
dc.contributor.author | Carabia Juberó, Júlia |
dc.contributor.author | Boix, Joan |
dc.contributor.author | Tazón Vega, Bárbara |
dc.contributor.author | Iacoboni García-Calvo, Gloria |
dc.contributor.author | Bobillo Varela, Sabela |
dc.contributor.author | González, Marcos |
dc.contributor.author | Zenz, Thorsten |
dc.contributor.author | Crespo Maull, Marta |
dc.contributor.author | Bosch Albareda, Francesc |
dc.contributor.author | Villacampa Javierre, Guillermo |
dc.contributor.author | Marin Niebla, Ana |
dc.date.accessioned | 2022-12-21T08:10:13Z |
dc.date.available | 2022-12-21T08:10:13Z |
dc.date.issued | 2022-11-08 |
dc.identifier.citation | Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, et al. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Nov 8;6(21):5763–73. |
dc.identifier.issn | 2473-9537 |
dc.identifier.uri | https://hdl.handle.net/11351/8701 |
dc.description | Expressió gènica; Leucèmia limfocítica crònica |
dc.description.sponsorship | This work was supported by research funding from the Asociación Española Contra el Cáncer grant [5U01CA157581-05, ECRIN-M3 - A29370] and in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A.], and the Spanish Ministry of Economy and Competitiveness [CIBERONC-CB16/12/00233], the Education Council or Health Council of the Junta de Castilla y León [GRS 2036/A/19], and Gilead Sciences [GLD15/00348]. This work was supported by research funding from the Asociación Española Contra el Cáncer grant [5U01CA157581-05, ECRIN-M3 - A29370] and in part by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias [PI17/00950, M.C., PI17/00943, F.B, PI18/01392, P.A.], and the Spanish Ministry of Economy and Competitiveness [CIBERONC-CB16/12/00233], the Education Council or Health Council of the Junta de Castilla y León [GRS 2036/A/19], Gilead Sciences [GLD15/00348] and Gilead Fellowships [GLD16/00144, GLD18/00047, F.B.], and Fundació la Marató de TV3 [201905-30-31 F.B]. All Spanish funding was cosponsored by the European Union FEDER program “Una manera de hacer Europa”. M.C. holds a contract from Ministerio de Ciencia, Innovación y Universidades [RYC-2012-2018]. |
dc.language.iso | eng |
dc.publisher | American Society of Hematology |
dc.relation.ispartofseries | Blood Advances;6(21) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Marcadors tumorals |
dc.subject | Expressió gènica |
dc.subject | Leucèmia limfocítica crònica |
dc.subject.mesh | Leukemia, Lymphocytic, Chronic, B-Cell |
dc.subject.mesh | /genetics |
dc.subject.mesh | Tumor Microenvironment |
dc.subject.mesh | Prognosis |
dc.subject.mesh | Gene Expression |
dc.title | A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1182/bloodadvances.2022007508 |
dc.subject.decs | leucemia linfocítica crónica de células B |
dc.subject.decs | /genética |
dc.subject.decs | microambiente tumoral |
dc.subject.decs | pronóstico |
dc.subject.decs | expresión génica |
dc.relation.publishversion | https://doi.org/10.1182/bloodadvances.2022007508 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Abrisqueta P, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, Bosch F] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Medina D, Carabia J, Boix J, Crespo M] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Villacampa G] Oncology Data Science (OdysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Lu J] European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. [Alcoceba M, González M] Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain. [Zenz T] Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland |
dc.identifier.pmid | 35973197 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00950 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00943 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01392 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |